Page 15 - சூரியன் மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sun Pharmaceuticals posted a 9.2 percent year on year rise in consolidated sales from operations in the December quarter to Rs 8,782 crore, the highest ever quarterly sales posted by the company, while its net profit grew by 102.8 per cent to Rs 1,852 crore. The India sales grew by 9.4 per cent to Rs 2,753 crore while the US finished dosage sales came in at $374 mn, up 7 per cent YoY. The Ebitda was up 36.3 per cent over last year same period to Rs 2,351 crore with a resulting Ebitda margin of 26.8 per cent. Asserting that the market is gradually recovering from the impact of the global pandemic Dilip Shanghvi, Managing Director, Sun Pharmaceuticals, pointed out, “Most of our businesses have done well over Q3 last year. Our global specialty sales have continued to show an improving trend and have crossed pre-Covid levels. Global Ilumya sales for nine months ended December 2020 have already crossed last full year’s sales.”

Sun pharmaDilip shanghviKirti ganorkarSun pharmaceuticalsManaging directorசூரியன் பார்மாநீர்த்துப்போக ஷாங்க்விகீர்த்தி கானோற்கார்சூரியன் மருந்துகள்நிர்வகித்தல் இயக்குனர்